8th Symposium 2022

Event Detail

December 1, 2022 9:00 am
December 3, 2022 9:00 pm
Parthenonos 19, Athina, GR 11742, Greece

Organizers

SCEP
info@scep.gr
00302107240039
https://scep.gr
The event is expired

The 8th Symposium “Advances in Cancer Immunology & Immunotherapy” is an intensive, three days interactive meeting during which invited speakers will address the current and accumulated knowledge of basic immuno-biology and translational cancer research, as well as therapeutic developments in the field of cancer immunotherapy according to the newest clinical trials.

The scientific objectives of the 8th Symposium “Advances in Cancer Immunology and Immunotherapy” are focused on the: (a) predictive and prognostic biomarkers for immunotherapy (b) mechanisms of action of different immunotherapeutic treatments (c) the efficacy and safety data of cancer immunotherapy regimens; and (d) strategies for immunomodulation, counteracting resistance and mitigating adverse events.

This year’s Symposium will feature world-renowned oncologists and researchers who will provide their insights on the above mentioned  topics in an effort to better understand tumor evolution and designing improved treatment strategies.

The 8th Symposium “Advances in Cancer Immunology and Immunotherapy” welcome the participation of scientists, clinicians, students and health care professionals interested in the field of Cancer Immunology and Immunotherapy.

The Organizing Committee

Athanasios Kotsakis
MD, PhD, Professor of Medical Oncology, School of Medicine, University of Thessaly, Larissa , Greece

Ourania Tsitsilonis
MD, PhD, Professor of Immunology, Department of Biology, National and Kapodistrian University of Athens, Greece

Constantin N. Baxevanis
Scientific Director, Cancer Immunology and Immunotherapy Center “St.Savvas” Cancer Hospital, Athens, Greece

Graham Pawelec
Professor of Experimental Immunology, Center of Medical Research, Department of Immunology, University of Tuebingen, Germany

Monica Neagu
Head of Immunology Department, “Victor Babes” National Institute of Pathology, Bucharest, Romania President of the Romanian Immunology Society, Romania

Suzanne Ostrand-Rosenberg
Adjunct Professor of Pathology Huntsman Cancer Institute (HCL),
University of Utah, USA

Jörg Wischhusen 
Professor of Experimental Tumor Immunology University of Würzburg School of Medicine Department of Gynecology and Obstetrics, Germany

Under the Auspices of

    Registration
    08.30 - 08.55
      Welcome address
      08.55 - 09.00
      Session 1: Tumor Immunity and Immunomodulation
      • Barbara Seliger
      Unraveling the role of oncogenes and tumor suppressor genes as a tool for immune evasion
      09.00 - 09.30
      Prof. Dr., Martin-Luther-Universität Halle-Wittenberg Institut für Medizinische Immunologie
      • Ioannis S. Pateras
      Understanding the inflammatory infiltrate in common solid cancers
      09.30 - 10.00
      • Noel de Miranda
      γδ T cells as effectors of immunity in colorectal cancer
      10.00 -10.30
      • Daniel Öhlund
      Immunomodulatory mechanisms in pancreatic cancer
      10.30 - 11.00
      M.D, Ph.D., Assistant Professor and Consultant Oncologist Wallenberg Molecular Medicine Fellow
      Coffee Break
      11.00 - 11.30
      Keynote Lecture
      • Hans-Georg Rammensee
      On the development of personalized cancer vaccines
      11.30 - 12.15
      Ph.D., Eberhard Karls University
      Session 2: Cancer Vaccines
      • Else Marit Inderberg
      Targeting Mutated GNAS for Treatment of Pseudomyxoma peritonei
      12.15 - 12.45
      Senior Scientist; PhD, Group leader & Head of Immunomonitoring
      • Pierre Coulie
      Tumor antigens: anything new?
      12.45 - 13.15
      PROFESSEUR ORDINAIRE ÉMÉRITE
      • Patrick Alexander Ott
      Personal Vaccines Targeting Neoantigens in Patients with Melanoma and other Solid Tumors
      13.15 - 13.45
      • Greg Kirchenbaum
      ImmunoSpot assays permit B cell affinity measurements
      13.45 - 14.15
      Ph.D, Director of Basic B cell Research
      Lunch Break
      14.15 - 15.15
      Short Presentations
      15.15 - 16.30
      • Panagiota Batsaki
      TCR REPERTOIRE AND IMMUNE-RELATED GENES AS PUTATIVE BIOMARKERS IN HEAD AND NECK CANCER
      15:15 - 15:25
        IMMUNE-GENE EXPRESSION AND TCR CLONOTYPES IN TUMOR MICROENVIRONMENT AND PERIPHERAL BLOOD IMMUNE CELLS IN HEAD AND NECK CANCER
        15.25 -15.35
        • Sophia Magkouta
        DIFFERENTIALLY EXPRESSED GENES AMONG HPV-POSITIVE AND HPV-NEGATIVE HEAD AND NECK CANCER PATIENTS
        15.35 - 15.45
        • Anastasia Xagara
        PRE-EXISTING CANCER-ANTIGEN SPECIFIC CD8+ T-CELLS AS A PREDICTIVE BIOMARKER FOR IMMUNOTHERAPY IN NSCLC PATIENTS
        15.45 - 15.55
        Postdoctoral Researcher at Laboratory of Oncology, Medical School of Thessaly, Larisa
        • Maria Goulielmaki
        ALTERATIONS IN THE TCR Vβ REPERTOIRE COMPOSITION OF NON-SMALL CELL LUNG CANCER PATIENTS AFTER IMMUNOTHERAPY
        15.55 - 16.05
        Postdoctoral Researcher at Cancer Immunology and Immunotherapy Center, Athens
        • Georgia Dimitrakopoulou
        BELANTAMAB MAFODOTIN INDUCES THE ICD OF MYELOMA CELLS IN MULTIPLE MYELOMA PATIENTS
        16.05 - 16.15
        Q & A
        16.15 - 16.30
        Session 3: Skin Neoplasms and Head and Neck Cancer - Current Status of Immunotherapy and Future Perspectives
        16.30 - 18.00
        • Helen Gogas
        Immunotherapy of Melanoma
        16.30-17.00
        • Amanda Psyrri
        Immunotherapy of Head and Neck Cancer
        17.00-17:30
        Professor of Medical Oncology, Chairman of Internal Medicine and Chief of Medical Oncology, Attikon University Hospital, Athens
        • Apostolos Laskarakis
        Immunotherapy of SCC - Sponsored by SANOFI
        17:30-18.00
        Director of Oncology Department at Athens Medical Group
        Coffee Break
        18.00-18.30
        Keynote Lecture
        • Ferdinandos Skoulidis
        Primary and secondary resistance to immunotherapy
        18.30 - 19.15
        M.D., Ph.D., MRCP, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
        Session 4: Cancer Biomarkers and Advances in Cancer Treatments
        • Monica Neagu
        The proteomic and genomic journey of a normal melanocyte to melanoma
        09.00-09.30
        Head of Immunology Department, "Victor Babes" National Institute of Pathology, Bucharest, Romania President of the Romanian Immunology Society
        • Teresa Frisan
        Microbes, cancer and the immune microenvironment
        09.30-10.00
        Professor at Department of Molecular Biology
        • Gilles Marodon
        Discovery and validation of Treg-oriented immune checkpoints for cancer immunotherapy
        10.00-10.30
        • Jörg Wischhusen
        Targeting TGF-beta superfamily members for cancer immunotherapy
        10.30-11.00
        Professor of Experimental Tumor Immunology University of Würzburg School of Medicine Department of Gynecology and Obstetrics
        Coffee Break
        11.00-11.30
        Keynote Lecture
        • Ulrich Keilholz
        Combination of targeted therapies and immunotherapies
        11.30-12.15
        Director Charité Comprehensive Cancer Center
        Session 5: Advances in Anti-cancer Immunotherapeutic Approaches
        • Gosse Adema
        Glyco-immune checkpoints in Cancer Immunotherapy
        12.15-12.45
        • Sophia Karagiannis
        Reprogramming macrophages with IgE antibody immunotherapy for cancer
        12.45-13.15
        Professor of Translational Cancer Immunology and Immunotherapy
        • Dimitrios Mastellos
        Complement therapeutics and their prospects for cancer immunotherapy
        13.15-13.45
        Director of Research at the National Center for Scientific Research ‘Demokritos’ in Athens
        • Panagiotis Verginis
        Treg cells in cancer and immune-related adverse events
        13.45-14.15
        IMBB Group Leader (Associate Professor, Medical School, Univ. of Crete)
        Light Lunch
        14.15-15.15
        Short Presentations
        • Junbiao Wang
        PRECLINICAL STUDY OF PHAGE-BASED VACCINES INDUCING THERAPEUTIC IMMUNITY AGAINST Δ16HER2-DRIVEN MAMMARY TUMORIGENESIS
        15.15-15.25
        • Michaela Surcel
        IMMUNE PATTERN IN CUTANEOUS MELANOMA
        15.25-15.35
        • Vassiliki Anastasopoulou
        TARGETING MUTANT P53 IN SPONTANEOUS CANCER BY T CELL RECEPTOR GENE THERAPY
        15.35-15.45
        • Ioannis Koukourakis
        RADIOTHERAPY, HLA-CLASS-I MOLECULES AND IFN-TYPE-I RESPONSE IN COLORECTAL CANCER CELL LINES
        15.45-15.55
        • Erasmia Xanthopoulou
        IFNγ, HIF1α AND PD-L1 EXPRESSION IN PROSTATE ANDROGEN-DEPENDENT AND INDEPENDENT CANCER CELL LINES
        15.55 - 16.05
        Q & A
        16.05 - 16.30
        Coffee Break
        16.30 - 17.00
        Session 6: Current Status of Immunotherapy and Future Perspectives in Selective Cancer
        • Alexios Matikas
        New data on ICIs in Breast Cancer
        17.00-17.30
        • Andre Thierry
        Immune Checkpoint Inhibitors in mismatch repair deficient solid tumors: current knowledge and future directions, an expert opinion - Sponsored by GSK
        17.30-18.00
        Coffee Break
        18:00 - 18:15
        Keynote Lecture
        • Lorenzo Galluzzi
        Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer
        18:15 - 19.00
        Session 7: Urinary Tract Neoplasms: Current Challenges and Future Perspectives
        19:00-20:00
        • Alexandra Drakaki
        Renal cancer and ICIs
        19:00-19:30
        • Petros Grivas
        Urothelial cancer and ICIs
        19:30-20:00
        Session 8: Intrinsic Regulation of Antitumor Immune Responses
        • Marianna Christodoulou
        IL-37: an immunoregulatory cytokine with a potential pathogenetic role in human cancers
        09.00-09.30
        European University Cyprus · Department of Life Sciences Biologist, MSc, PhD
        • Vincenzo Bronte
        Myeloid deviation in Cancer and Covid-19
        09.30-10.00
        • Viktor Umansky
        Targeting MDSCs to improve cancer immunotherapy
        10.00-10.30
        • Suzanne Ostrand-Rosenberg
        Tumor induced immune suppression: the problem is RAGE
        10.30-11.00
        Adjunct Professor of Pathology Huntsman Cancer Institute (HCL), University of Utah
        • Annette Paschen
        The role of chromosomal aberrations in melanoma resistance to immunotherapy
        11.00-11.30
        Coffee Break
        11.30-12.00
        Keynote Lecture
        • Alejandro Madrigal
        Beyond CAR-T Cells a novel approach to develop off the shelf iPSC CAR-NK cells
        12.00-12.45
        Session 9: Extrinsic Regulation of Antitumor Immune Responses
        • Michael Koukourakis
        Cancer Immuno-Radiotherapy: Balancing between immunosuppression and radio-vaccination
        12.45-13.15
        Professor of Radiation Oncology, Medical School, Democritus University of Thrace, Alexandroupolis
        • Christoph Reinhardt
        Epithelial Toll-like receptor-2 as a regulator of intestinal epithelial renewal and its role in colorectal cancer
        13.15-13.45
        Proffesor Center for Thrombosis and Hemostasis Mainz (CTH) University Medical Center of the Johannes Gutenberg University Mainz
        • Maria Goulielmaki
        Immunotherapy- induced alterations in the TCR Vβ repertoire of non-small cell lung cancer patients
        13.45-14.15
        Postdoctoral Researcher at Cancer Immunology and Immunotherapy Center, Athens
        Lunch Break
        14.15-15.15
        Short Presentations
        15.15-16.30
        • Carolina Constantin
        PHENOTYPIC CHANGES IN TUMOR-PRIMED MURINE NK CELLS
        15:15 - 15:25
        • Pantellis Rousakis
        ASSESSING MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA WITH NEXT-GENERATION FLOW CYTOMETRY: A REPORT OF INTERESTING CASES
        15:25-15:35
        • Pigi - Maria Niotopoulou
        IMMUNOPHENOTYPIC COMPARISON OF HUMAN AND CANINE LYMPHOMAS WITH FLOW CYTOMETRY
        15.35-15.45
        • Evangelia Nikou
        STUDY OF THE ANTI-NEOPLASTIC ACTIVITY OF OLEUROPEIN ANALOGUES IN VITRO
        15.45-15.55
        • Odyssefs Liagkas
        IN VIVO INVESTIGATION OF THE ANTI-CANCER ACTIVITY OF GS32, A NOVEL SEMI-SYNTHETIC ANALOGUE OF OLEUROPEIN
        15.55-16.05
        Q & A
        16.05-16.30
        Session 10: Immunotherapy in Lung Cancer: Current Challenges and Future Perspectives
        • Luis Paz-Ares
        The value of the immunotherapy in SCLC treatment: meeting the expectations - Sponsored by ASTRA ZENECA
        16.30-17.00
        • Sebahat Ocak
        NSCLC with high expression ≥ 50% of PD-L1 - Sponsored by SANOFI
        17.00-17.30
        • Dionysios Papadatos - Pastos
        First-line treatment of NSCLC: What is the preferred regimen?
        17:30-18:00
        • Maya Gottfried
        IO benefit in metastatic and earlier stages NSCLC - Sponsored by BMS
        18:00-18:30
        Coffee Break
        18:30-18:45
        Session 11: Cancer Immunotherapy in 2022 and a look ahead
        • Teresa Whiteside
        Tumor-derived exosomes in plasma of cancer patients induce stress and death in immune cells: danger from within
        18:45- 19:15
        Professor, Department of Immunology, University of Pittsburgh
        • Paul Victor Lehmann
        A renaissance for B cell immune monitoring and its perspective for tumor immunology
        19:15-19:45
        • Jörg Wischhusen
        What have we learned this week?
        19:45-20:15
        Professor of Experimental Tumor Immunology University of Würzburg School of Medicine Department of Gynecology and Obstetrics
        Abstract Awards: Organizing Committee
        20:15-20:30
        Concluding Remarks: Organizing Committee
        20:30 - 20:45
        Jörg Wischhusen

        Jörg Wischhusen

        Professor of Experimental Tumor Immunology University of Würzburg School of Medicine Department of Gynecology and Obstetrics
        Suzanne Ostrand-Rosenberg

        Suzanne Ostrand-Rosenberg

        Adjunct Professor of Pathology Huntsman Cancer Institute (HCL), University of Utah
        Monica Neagu

        Monica Neagu

        Head of Immunology Department, "Victor Babes" National Institute of Pathology, Bucharest, Romania President of the Romanian Immunology Society
        Amanda Psyrri

        Amanda Psyrri

        Professor of Medical Oncology, Chairman of Internal Medicine and Chief of Medical Oncology, Attikon University Hospital, Athens
        Apostolos Laskarakis

        Apostolos Laskarakis

        Director of Oncology Department at Athens Medical Group
        Maria Goulielmaki

        Maria Goulielmaki

        Postdoctoral Researcher at Cancer Immunology and Immunotherapy Center, Athens
        Anastasia Xagara

        Anastasia Xagara

        Postdoctoral Researcher at Laboratory of Oncology, Medical School of Thessaly, Larisa
        Teresa Whiteside

        Teresa Whiteside

        Professor, Department of Immunology, University of Pittsburgh
        Ferdinandos Skoulidis

        Ferdinandos Skoulidis

        M.D., Ph.D., MRCP, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
        Barbara Seliger

        Barbara Seliger

        Prof. Dr., Martin-Luther-Universität Halle-Wittenberg Institut für Medizinische Immunologie
        Daniel Öhlund

        Daniel Öhlund

        M.D, Ph.D., Assistant Professor and Consultant Oncologist Wallenberg Molecular Medicine Fellow
        Hans-Georg Rammensee

        Hans-Georg Rammensee

        Ph.D., Eberhard Karls University
        Pierre Coulie

        Pierre Coulie

        PROFESSEUR ORDINAIRE ÉMÉRITE
        Teresa Frisan

        Teresa Frisan

        Professor at Department of Molecular Biology
        Ulrich Keilholz

        Ulrich Keilholz

        Director Charité Comprehensive Cancer Center
        Greg Kirchenbaum

        Greg Kirchenbaum

        Ph.D, Director of Basic B cell Research
        Dimitrios Mastellos

        Dimitrios Mastellos

        Director of Research at the National Center for Scientific Research ‘Demokritos’ in Athens
        Marianna Christodoulou

        Marianna Christodoulou

        European University Cyprus · Department of Life Sciences Biologist, MSc, PhD
        Michael Koukourakis

        Michael Koukourakis

        Professor of Radiation Oncology, Medical School, Democritus University of Thrace, Alexandroupolis
        Christoph Reinhardt

        Christoph Reinhardt

        Proffesor Center for Thrombosis and Hemostasis Mainz (CTH) University Medical Center of the Johannes Gutenberg University Mainz
        Panagiotis Verginis

        Panagiotis Verginis

        IMBB Group Leader (Associate Professor, Medical School, Univ. of Crete)
        Else Marit Inderberg

        Else Marit Inderberg

        Senior Scientist; PhD, Group leader & Head of Immunomonitoring
        Sophia Karagiannis

        Sophia Karagiannis

        Professor of Translational Cancer Immunology and Immunotherapy